About CinCor
CinCor is a Healthcare company based in Cincinnati (United States) founded in 2018 by Jon Isaacsohn, and was acquired by Astrazeneca in January 2023. Therapeutics for cardio-renal diseases, including hypertension treatments, are developed. CinCor has raised $193 million across 2 funding rounds from investors including Astrazeneca, General Atlantic and CinRx Pharma. The company has 15 employees. Its chief executive, as recorded, is Jon Isaacsohn. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is CINCOR PHARMA, INC. Its competitors include Portola Pharma, MyoKardia and Cellino; 3 of its 3 listed competitors have raised funding.
Company details
CinCor was founded in 2018 in Cincinnati, United States, within the biotechnology sector. Focus is placed on developing therapeutics for cardio-renal diseases. The lead candidate, CIN-170, functions as an aldosterone synthase inhibitor targeting the renin-angiotensin-aldosterone system. Applications include treatments for hypertension, kidney diseases, and associated conditions, with operations centered in the United States.
- Headquarters Cincinnati, United States
- Employees 15
- Founders Jon Isaacsohn
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cincor.com
- Acquired by Astrazeneca (Jan 2023)
- Legal Name Cincor Pharma, Inc.
- Net Profit-$50.37 M (USD)-126as on Dec 31, 2021
- EBITDA-$42.51 M (USD)-101as on Dec 31, 2021
- Total Equity Funding$193M (USD)
in 2 rounds
- Latest Funding Round$143M (USD), Series B
Oct 2021
- InvestorsAstrazeneca
& 14 more
- Employee Count15
- Acquired byAstrazeneca
(Jan 2023)
Funding Insights of CinCor
CinCor has successfully raised a total of $193M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $143 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $193M
- Total Rounds 2
- Last Round Series B — $143M
- First Round $50M
(May 2019)
- Investors Count 14
All 2 funding rounds of CinCor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $143M | Series B | – | General Atlantic | |
| May 2019 | $50M | Series A | – | Sofinnova Investments |
15 investors in total: 15 institutional.
Investors in CinCor
CinCor has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, General Atlantic and CinRx Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital firm | omegafunds.com | Boston, United States | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital fund focused on tech startups | sixtydegreecapital.com | North York, Canada |
Investor details for CinCor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CinCor
14 people are tracked at CinCor (4 in leadership, 8 in board & advisors, 2 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Jon Isaacsohn | Co-Founder & CEO | Leadership |
Marc De Garidel | CEO | Leadership |
Yuan-Di Halvorsen | VP, Clinical Operations | Leadership |
Kevin Schutz, PharmD | Vice President Regulatory Affairs | Leadership |
August Troendle | Director | Board & advisors |
Suzanne Oparil | Scientific Advisor | Board & advisors |
Ulrich Granzer | Scientific Advisor | Board & advisors |
Morris Brown | Scientific Advisor | Board & advisors |
Philip T. Sager | Scientific Advisor | Board & advisors |
Bryan Williams | Scientific Advisor | Board & advisors |
John Kastelein | Scientific Advisor | Board & advisors |
Patrick Rossignol | Scientific Advisor | Board & advisors |
Jonathan Isaacsohn | CSO | Team |
Mason W. Freeman | EVP, Clinical Operations | Team |
Complete people profiles for CinCor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CinCor
5 dated milestones of CinCor across 5 years, from founding to its latest funding, stage changes and deals.
- Founded CinCor is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series B, of $143.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Astrazeneca.
Competitors of CinCor
CinCor has 3 listed competitors in our database, 3 of them funded. They include Portola Pharma, MyoKardia and Cellino.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies |
Detailed competitors of CinCor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as CinCor (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cincor
Complete news archive for CinCor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CinCor
CinCor was founded in 2018 and raised its 1st funding round 1 year after it was founded.
CinCor is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Jon Isaacsohn is the CEO of CinCor, as recorded in our data. They have also founded this company.
CinCor is a funded company, having raised a total of $193M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on May 2019.
CinCor has 15 employees.
CinCor was founded in 2018 in Cincinnati, United States, within the biotechnology sector. Focus is placed on developing therapeutics for cardio-renal diseases. The lead candidate, CIN-170, functions as an aldosterone synthase inhibitor targeting the renin-angiotensin-aldosterone system. Applications include treatments for hypertension, kidney diseases, and associated conditions, with operations centered in the United States.
CinCor's top competitors include Cellino, MyoKardia and Portola Pharma.
CinCor has 15 investors. Key investors include Astrazeneca, General Atlantic, CinRx Pharma, RTW Investments, and Perceptive Advisors.
CinCor operates through Cincor Pharma, Inc..
Yes. CinCor was acquired by Astrazeneca in January 2023.